Li‐Fraumeni and Li‐Fraumeni—like syndrome among children diagnosed with pediatric cancer in Southern Brazil

Pediatric cancers are a feature in patients with Li‐Fraumeni syndrome and its variant Li‐Fraumeni–like syndrome (LFS/LFL). To the best of the authors' knowledge, TP53 germline mutations are currently the only molecular defect known to be associated with this disease. Recently, a specific germline mutation in this gene, p.R337H, has been reported at a high prevalence in Brazil.

[1]  G. C. Piovezan.  Prevalencia do alelo TP53 R337H no estado do Parana , 2013 .

[2]  M. Fassnacht,et al.  TP53 germline mutations in adult patients with adrenocortical carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  M. Fassnacht,et al.  Clinical impact of TP53 alterations in adrenocortical carcinomas , 2012, Langenbeck's Archives of Surgery.

[4]  J. A. Yunes,et al.  Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil , 2011, Cancer.

[5]  E. Lalli,et al.  Increased Incidence of Choroid Plexus Carcinoma Due to the Germline TP53 R337H Mutation in Southern Brazil , 2011, PloS one.

[6]  P. Babyn,et al.  Imaging of cancer predisposition syndromes in children. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[7]  M. Olivier,et al.  Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect , 2010, Human mutation.

[8]  Catherine Bonaïti-Pellié,et al.  2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Shurtleff,et al.  Association of the germline TP53 R337H mutation with breast cancer in southern Brazil , 2008, BMC Cancer.

[11]  C. Bonaïti‐pellié,et al.  Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families , 2008, Journal of Medical Genetics.

[12]  M. Olivier,et al.  Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. , 2008, Cancer letters.

[13]  M. Olivier,et al.  The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. , 2007, Cancer letters.

[14]  Andrew Shenton,et al.  BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. , 2006, European journal of cancer.

[15]  P. Boffetta,et al.  Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation , 2005, Journal of Medical Genetics.

[16]  Charis Eng,et al.  Highly penetrant hereditary cancer syndromes , 2004, Oncogene.

[17]  D. Evans,et al.  Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome , 2002, Journal of medical genetics.

[18]  E. Pinto,et al.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[19]  J. Varley,et al.  Relative frequency and morphology of cancers in carriers of germline TP53 mutations , 2001, Oncogene.

[20]  O. Delattre,et al.  [Li-Fraumeni syndrome: update, new data and guidelines for clinical management]. , 2001, Bulletin du cancer.

[21]  C. Bonaïti‐pellié,et al.  Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.

[22]  C. Bonaïti‐pellié,et al.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals , 2000, British Journal of Cancer.

[23]  D. Parkin,et al.  Epidemiology of cancer: global patterns and trends. , 1998, Toxicology letters.

[24]  J. Fraumeni,et al.  Multiple primary cancers in families with Li-Fraumeni syndrome. , 1998, Journal of the National Cancer Institute.

[25]  D. Evans,et al.  Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. , 1997, Cancer research.

[26]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[27]  C. Marshall.  Tumor suppressor genes , 1991, Cell.

[28]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[29]  D. Parkin,et al.  The international incidence of childhood cancer , 1988, IARC scientific publications.

[30]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[31]  J. Fraumeni,et al.  Prospective study of a family cancer syndrome. , 1982, JAMA.

[32]  Illinois.,et al.  Cancer Genetics , 1976, British Journal of Cancer.

[33]  J. Fraumeni,et al.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969 .

[34]  L. Strong.  General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. , 2003, Gynecologic oncology.

[35]  J. Varley.  TP53, hChk2, and the Li-Fraumeni syndrome. , 2003, Methods in molecular biology.

[36]  W. Mcdougal.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.

[37]  Bruce A.J. Ponder,et al.  Cancer genetics , 2001, Nature.

[38]  R. Eeles.  Germline mutations in the TP53 gene. , 1995, Cancer surveys.

[39]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.